Actively Recruiting
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
Led by Mu-qing Yang · Updated on 2026-02-06
260
Participants Needed
1
Research Sites
302 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients. Accurately identifying high-risk patients for metastasis and intervening in them has important clinical significance. The pathological examination of surgical specimens failed to fully utilize valuable specimen information and accurately predict liver metastasis; The biomarkers secreted by tumors are metabolized in the liver through the portal vein, especially the particles such as extracellular vesicles secreted by tumors, which are ultimately diluted in peripheral blood and cannot be effectively detected. Our research group extracted an average of 11.25ml of blood (named blood derived from portal vein branch specimens, sdBlood for short) from 8 colorectal cancer radical surgery specimens. Compared with peripheral blood, protein mass spectrometry analysis revealed a significant increase in exosome proteins such as peroxidized redox protein 1 (PRDX1), which are highly correlated with metastasis. This project innovatively uses sdBlood, which has been overlooked by routine pathological examination, to detect the exosomal protein PRDX1 in sdBlood, which is significantly higher than the peripheral blood concentration. A prospective cohort study was established, including 252 patients with pathologically confirmed colorectal cancer after radical surgery. The incidence and time of liver metastasis were followed up and observed. Cox regression statistical analysis was used to determine the correlation between this marker and metastasis and determine its critical value, providing a basis for clinical diagnosis and treatment.
CONDITIONS
Official Title
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 19 and 80 years old
- Ability to follow the research visit plan and study protocols
- Voluntary participation with signed informed consent
- Diagnosis of colon adenocarcinoma confirmed by pathological examination
- Completion of colorectal radical surgery
You will not qualify if you...
- Unable to complete radical surgery for colorectal cancer
- Presence of liver diseases such as chronic hepatitis B, hepatitis C, severe fatty liver, or cirrhosis
- Need for combined organ resection
- Having other malignant tumors or blood or immune system diseases
- Prior anti-tumor treatments before tumor resection, including radiotherapy, chemotherapy, or molecular targeted therapy
- Inability to obtain blood from mesenteric vein branch of the specimen due to severe infiltration or other reasons
- Severe postoperative complications causing delayed treatment (Clavien-Dindo grade III or above)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Tongji Hospital, Hepatobilliary Surgery Center, Tongji University
Shanghai, Shanghai Municipality, China, 200065
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here